Meridian Activation Remedy System for Parkinson's Disease — A Randomized Controlled Trial

Meridian Activation Remedy System for Parkinson's Disease — A Single-center, Rater-blinded, Parallel Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006646

Enrollment

Registered

2021-10-07

Start date

2022-04-08

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others(Meridian Activation Remedy System for Parkinson's Disease(MARS-PD)) : Experimental group: Meridian Activation Remedy System for Parkinson's Disease(MARS-PD) treatment (16 times/8 weeks total, 2

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 45 to 75 years of age 2) Patients with PD, diagnosed according to the UK Parkinson’s Diseases Society Brain Bank Criteria 3) Hoehn and Yahr scale stage I to III 4) Patients who have voluntarily decided to participate in the clinical study and signed the informed consent form

Exclusion criteria

Exclusion criteria: 1) Clinically unstable patients (e.g., elevated aspartate transaminase(AST) or alanine aminotransferase(ALT) more than three-fold the upper limit of normal in the research institute's laboratory, heart failure, respiratory failure, etc.) 2) Patients who are planning to undergo deep brain stimulation within the study period 3) Pregnant or lactating women 4) Patients with MMSE-K(Mini-Mental State Exam) score of 18 or less 5) If there has been a change in the dosage of antiparkinsonian drugs (e.g., L-dopa, COMT inhibitor, Dopamine agonist, MAO-B inhibitor, etc.) according to a doctor's prescription within the last 4 weeks prior to enrollment 6) Patients who are receiving manual therapy, exercise therapy, or rehabilitation therapy for Parkinson's disease according to a doctor's prescription within the last 4 weeks prior to enrollment, or are planning to receive such therapy within the study period 7) Patients who are not suitable for participation in this clinical study according to the judgment of the researcher

Design outcomes

Primary

Measure	Time frame
MDS-UPDRS(Movement Disorder Society Unified Parkinson’s Disease Rating Scale) Part ?	—

Secondary

Measure	Time frame
MDS-UPDRS(Movement Disorder Society Unified Parkinson’s Disease Rating Scale) Part ?;IPAQ(International Physical Activity Questionnarie Short Form);Parkinson Self Questionnaire;PDSS(Parkinson’s disease Sleep Scale);TUG(Timed up and go test);GAITRite(GAITRite Electronic Walkway Platinum);fNIRS(Functional near-infrared spectroscopy);Smartband outcomes(number of steps per day, daily sleep hours, sleep pattern, etc);Iris imaging 1;Iris imaging 2;MDS-UPDRS(Movement Disorder Society Unified Parkinson’s Disease Rating Scale);Gut microbiome test	—

Measure

Time frame

MDS-UPDRS(Movement Disorder Society Unified Parkinson’s Disease Rating Scale) Part ?;IPAQ(International Physical Activity Questionnarie Short Form);Parkinson Self Questionnaire;PDSS(Parkinson’s disease Sleep Scale);TUG(Timed up and go test);GAITRite(GAITRite Electronic Walkway Platinum);fNIRS(Functional near-infrared spectroscopy);Smartband outcomes(number of steps per day, daily sleep hours, sleep pattern, etc);Iris imaging 1;Iris imaging 2;MDS-UPDRS(Movement Disorder Society Unified Parkinson’s Disease Rating Scale);Gut microbiome test

—

Countries

Korea, Republic of

Contacts

Public ContactMiso Park

Daejeon Korean Medicine Hospital of Daejeon University

miso.sophia.park@gmail.com+82-42-470-9541

Outcome results